243 related articles for article (PubMed ID: 28210799)
1. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.
Kuchcinski G; Le Rhun E; Cortot AB; Drumez E; Duhal R; Lalisse M; Dumont J; Lopes R; Pruvo JP; Leclerc X; Delmaire C
Eur Radiol; 2017 Sep; 27(9):3733-3743. PubMed ID: 28210799
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of Hemangioblastoma from Metastatic Brain Tumor using Dynamic Contrast-enhanced MR Imaging.
Cha J; Kim ST; Nam DH; Kong DS; Kim HJ; Kim YK; Kim HY; Park GM; Jeon P; Kim KH; Byun HS
Clin Neuroradiol; 2017 Sep; 27(3):329-334. PubMed ID: 26952018
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced MRI perfusion for differentiating between melanoma and lung cancer brain metastases.
Hatzoglou V; Tisnado J; Mehta A; Peck KK; Daras M; Omuro AM; Beal K; Holodny AI
Cancer Med; 2017 Apr; 6(4):761-767. PubMed ID: 28303695
[TBL] [Abstract][Full Text] [Related]
5. Prognostic aspects of dynamic contrast-enhanced magnetic resonance imaging in synchronous distant metastatic rectal cancer.
Yu J; Xu Q; Huang DY; Song JC; Li Y; Xu LL; Shi HB
Eur Radiol; 2017 May; 27(5):1840-1847. PubMed ID: 27595835
[TBL] [Abstract][Full Text] [Related]
6. Assessment of irradiated brain metastases using dynamic contrast-enhanced magnetic resonance imaging.
Almeida-Freitas DB; Pinho MC; Otaduy MC; Braga HF; Meira-Freitas D; da Costa Leite C
Neuroradiology; 2014 Jun; 56(6):437-43. PubMed ID: 24652530
[TBL] [Abstract][Full Text] [Related]
7. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
El Khouli RH; Macura KJ; Kamel IR; Jacobs MA; Bluemke DA
AJR Am J Roentgenol; 2011 Dec; 197(6):1498-505. PubMed ID: 22109308
[TBL] [Abstract][Full Text] [Related]
8. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
9. [Application on the quantitative perfusion parameters of dynamic contrast-enhanced MRI in the pathological subtype of uterine leiomyoma].
Zheng J; Zhao ZH; Yang JF; Zhao L; Yang LM; Hu HJ
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(15):1155-1159. PubMed ID: 28427122
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Hirashima Y; Yamada Y; Tateishi U; Kato K; Miyake M; Horita Y; Akiyoshi K; Takashima A; Okita N; Takahari D; Nakajima T; Hamaguchi T; Shimada Y; Shirao K
Int J Cancer; 2012 May; 130(10):2359-65. PubMed ID: 21780098
[TBL] [Abstract][Full Text] [Related]
11. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density.
Chen J; Chen C; Xia C; Huang Z; Zuo P; Stemmer A; Song B
Abdom Radiol (NY); 2018 Jun; 43(6):1393-1403. PubMed ID: 28939963
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced 3-T MR imaging in cervical cancer before and after concurrent chemoradiotherapy.
Kim JH; Kim CK; Park BK; Park SY; Huh SJ; Kim B
Eur Radiol; 2012 Nov; 22(11):2533-9. PubMed ID: 22653283
[TBL] [Abstract][Full Text] [Related]
13. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
15. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
16. Temporal evolution of perfusion parameters in brain metastases treated with stereotactic radiosurgery: comparison of intravoxel incoherent motion and dynamic contrast enhanced MRI.
Kapadia A; Mehrabian H; Conklin J; Symons SP; Maralani PJ; Stanisz GJ; Sahgal A; Soliman H; Heyn CC
J Neurooncol; 2017 Oct; 135(1):119-127. PubMed ID: 28669014
[TBL] [Abstract][Full Text] [Related]
17. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of quantitative dynamic contrast-enhanced magnetic resonance imaging for the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer].
Zhu YJ; Li Y; Jiang J; Zhang W; Xue LY; Zhou AP; Jiang LM
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):765-770. PubMed ID: 31648499
[No Abstract] [Full Text] [Related]
19. Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.
Artzi M; Liberman G; Nadav G; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
J Neurooncol; 2016 May; 127(3):515-24. PubMed ID: 26754857
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic value of quantitative pharmacokinetic parameters and relative quantitative pharmacokinetic parameters in breast lesions with dynamic contrast-enhanced MRI].
Sun TT; Liu WH; Zhang YQ; Li LH; Wang R; Ye YY
Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(29):2266-2270. PubMed ID: 28780840
[No Abstract] [Full Text] [Related]
[Next] [New Search]
